The FDA has yet to approve it, but often heeds recommendations of its advisory committees. FDA approval may be a year away.
ExuberaTM is the first inhalable insulin to make it this far in the route to FDA approval. Novo Nordisk (with Aradigm) and Eli Lilly (with Alkermes) also have inhalable drugs in development.
Pfizer's press release:
FDA Advisory Committee Recommends Approval of Exubera® for Use in Adults with Type 1 and 2 Diabetes
Novo Nordisk and Aradigm's press release:
Aradigm Announces Novo Nordisk Presentation of Data of AERx Insulin Diabetes Management System at the American Diabetes Association Annual Meeting
Eli Lilly and Alkermes's press release:
Lilly and Alkermes Initiate Phase 3 Safety Study for Inhaled Insulin